Other grades of this product :
| BAY 73-6691 Basic information |
| Product Name: | BAY 73-6691 | | Synonyms: | 1-(2-Chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one;(R)-BAY 73-6691;4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1-(2-chlorophenyl)-1,5-dihydro-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-;BAY 73-6691 >=98% (HPLC), powder | | CAS: | 794568-92-6 | | MF: | C15H12ClF3N4O | | MW: | 356.73 | | EINECS: | | Product Categories: | | Mol File: | 794568-92-6.mol |
| BAY 73-6691 Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMSO: >20mg/mL | | form | powder | | color | off-white |
| Hazard Codes | T,Xi | | Risk Statements | 25-36/37/38 | | Safety Statements | 26-45 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 |
| BAY 73-6691 Usage And Synthesis |
| Uses | BAY 73-6691 has been used as a phosphodiesterase 9 inhibitor in ischemic heart samples and in structural studies. It may be used as a PDE 9 inhibitor in neuroblastoma?SH-SY5Y cells. | | Biochem/physiol Actions | BAY 73-6691 was characterized in vitro as the first potent and selective inhibitor of phosphodiesterase 9 (PDE9), which is currently under preclinical development for the treatment of Alzheimer′s disease. This compound selectively inhibits human (IC50 = 55 nM) and murine (IC50 = 100 nM) PDE9 activity in vitro and shows only moderate activity against other cyclic nucleotide-specific phosphodiesterases. BAY 73-6691 alone did not significantly increase basal cGMP levels. The PDE9 inhibitor significantly potentiated the cGMP signals generated by sGC activating compounds such as BAY 58-2667 or 5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine (BAY 41-2272) and induced leftward shifts of the corresponding concentration-response curves. The newly generated PDE9 reporter cell line show that BAY 73-6691 is able to efficiently penetrate cells and to inhibit intracellular PDE9 activity. |
| BAY 73-6691 Preparation Products And Raw materials |
|